Biotinylated Human Siglec-3 / CD33 Protein, Avitag™,His Tag (MALS verified)
分子别名（Synonym）
CD33,SIGLEC3,gp67
表达区间及表达系统（Source）
Biotinylated Human Siglec-3, Avitag,His Tag (CD3-H82E7) is expressed from human 293 cells (HEK293). It contains AA Asp 18 - His 259 (Accession # AAH28152.1).
Predicted N-terminus: Asp 18
蛋白结构（Molecular Characterization）
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 29.4 kDa. The protein migrates as 45-55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
内毒素（Endotoxin）
Less than 0.1 EU per μg by the LAL method / rFC method.
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介绍
髓系细胞表面抗原CD33（亦称SIGLEC3、Siglecs唾液酸结合免疫球蛋白样凝集素、GP67）是一种属于免疫球蛋白超家族及SIGLEC（唾液酸结合免疫球蛋白样凝集素）家族的I型跨膜蛋白。人源CD33/Siglec-3 cDNA编码的364个氨基酸多肽包含疏水信号肽、N端Ig样V型结构域、一个Ig样C2型结构域、跨膜区及胞质尾段。CD33/Siglec-3通常被认为是髓系特异性抗原，但也存在于部分淋巴样细胞表面。在免疫应答中，CD33/Siglec-3可通过配体诱导的酪氨酸磷酸化招募胞质磷酸酶（借助其SH2结构域），使信号分子去磷酸化从而阻断信号传导，进而发挥抑制性受体功能。CD33/Siglec-3能够诱导急性髓系白血病细胞发生凋亡。
关键字： Siglec-3;Siglec-3蛋白;Siglec-3重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。